Abstract:Chong Li, 1, 2, &ast Shu Lai, 3, &ast Ruokun Yi, 1 Xianrong Zhou, 1, 2 Xin Zhao, 1 Qiang Li 4 1 Collaborative Innovation Center for Child Nutrition and Health Development, Chongqing Engineering Research Center of Functional Food, Chongqing Engineering Laboratory for Research and Development of Functional Food, Chongqing University of Education, Chongqing, People's Republic of China; 2 Department of Food and Nutrition, College of Medical and Life Science, Silla University, Busan, Republic of Korea; 3 Department of Pharmacology, Jiulongpo District People's Hospital of Chongqing, Chongqing, People's Republic of China; 4 Department of Emergency, The First Affiliated Hospital of Gannan Medical College, Ganzhou, Jiangxi, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xin Zhao; Qiang Li, Email ; Objective: The liver protection of blood coral polysaccharide (BCP) was investigated. Materials and Methods: We evaluated the effect of BCP on liver pathology, liver function, oxidation and inflammation-related indicators of D-Gal/LPS-induced acute liver failure (ALF) mice in vivo. Results: Liver index and liver pathology observation in mice showed that BCP could inhibit liver tissue swelling and hemorrhage, hepatocyte damage, and inflammatory infiltration in ALF. Serum liver function results showed that BCP effectively inhibits the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), total bilirubin (TBil), alkaline phosphatase (AKP), myeloperoxidase (MPO). High dose-blood coral polysaccharide (H-BCP) was better than silymarin. Serum antioxidant and immune results showed that BCP increased the levels of superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), and glutathione peroxidase (GSH-Px), and inhibited the levels of malondialdehyde (MDA) and nitric oxide (NO). Also, BCP increased immunoglobulins G (IgG) and A (IgA) levels, thereby enhancing humoral immunity. Liver anti-inflammatory ELISA results showed that BCP reduced the levels of interleukin (IL)-6, IL-1β, IL-17, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ, and enhanced the level of anti-inflammatory factor IL-10. H-BCP was the most effective treatment. Real-time quantitative reverse transcription-polymerase chain reaction (RT-qPCR) of liver tissues confirmed that BCP increases the relative expression levels of antioxidant and anti-inflammatory-related cuprozinc superoxide dismutase (Cu/Zn-SOD, SOD1), manganese superoxide dismutase (Mn-SOD, SOD2), CAT, GSH, GSH-Px, and IL-10. In contrast, it inhibits inflammation-related genes IL-6, IL-1β, IL-17, TNF-α, IFN-γ, inducible nitric oxide synthase (iNOS, NOS2), and cyclooxygenase (COX)-2. In addition, BCP also inhibits the nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) and enhance B-cell inhibitor-α (IκB-α) gene relative expression in the liver, which may be related to NF-κB pathway inhibition. Conclusion: BCP prevents D-Gal/LPS-induced ALF in mice, and its effect is concentration dependent. Keywords: blood coral polysaccharide, acute liver failure, antioxidant, anti-inflammatory, immunomodulatory Massive hepatocyte necrosis and severe liver dysfunction cause acute liver failure (ALF), often accompanied by hepatic encephalopathy. ALF is most common in young and middle-aged patients with liver disease. The clinical course is progressive multiple organ failure, with rapid onset, poor prognosis, and high mortality. There are no specific treatments, and most of them focus on maintaining the patient's vital functions, expecting liver function recovery, or liver transplantation. Defining ALF pathogenesis and finding effective treatment methods are currently the focus of researchers. 1 The combined D-galactose/Lipopolysaccharide (D-Gal/LPS) ALF induction model is simple to operate and has good reproducibility, making it the preferred ALF animal model. High levels of D-Gal are converted to aldose and hydroperoxides catalyzed by galactose oxidase in the liver, generating reactive oxygen species (ROS). 2 In addition, advanced glycation end products (AGEs) formed by the D-Gal reaction in vivo also exacerbate the oxidation process. 3 LPS is a pathogen-associated molecular pattern (PAMP), which mediates the innate immune response and induces inflammatory mediators by activating mononuclear phagocytic system (MPS) release and eventually developing ALF. 4 Most rodents are naturally resistant to LPS, so D-Gal sensitization combined with low-dose LPS is often used to establish an ALF animal model. D-Gal increases mice -Abstract Truncated-

Caloric restriction mimetic 2-deoxyglucose alleviated lethal liver injury induced by lipopolysaccharide/D-galactosamine in mice

The effect of histone deacetylase inhibitor ACY1215 on the inflammatory response in mice with acute liver failure

Effect of Ercao Qinggan Decoction on Acute Liver Injury of Mice with Endotoxemia and the Expression of TLR4 in the Liver

Short-term Use of MyD88 Inhibitor TJ-M2010-5 Prevents D-Galactosamine/lipopolysaccharide-induced Acute Liver Injury in Mice.

2-deoxy-D-Glucose-(2-DG) Prevents Pathogen Driven Acute Inflammation and Associated toxicity

Dietary administration of the glycolytic inhibitor 2-deoxy-D-glucose reduces endotoxemia-induced inflammation and oxidative stress: Implications in PAMP-associated acute and chronic pathology

Oral administration of grape-derived nanovesicles for protection against LPS/D-GalN-induced acute liver failure

[Protective effect of glycogen synthase kinase 3β inhibition via peroxisome proliferator-activated receptor alpha activation in mice with acute liver failure].

[Liver Fibrosis Inhibits Lethal Injury Through D-galactosamine/lipopolysaccharide-induced Necroptosis].

Tectorigenin Protects Against Experimental Fulminant Hepatic Failure by Regulating the TLR4/mitogen‐activated Protein Kinase and TLR4/nuclear Factor‐κb Pathways and Autophagy

[2-DG improves lung ischemia/reperfusion injury by inhibiting NLRP3-mediated pyroptosis in rats]

Calorie restriction protects against acute systemic LPS-induced inflammation

Selective PPARδ Agonist GW501516 Protects Against LPS-Induced Macrophage Inflammation and Acute Liver Failure in Mice via Suppressing Inflammatory Mediators

Silencing of GDF11 suppresses hepatocyte apoptosis to relieve LPS/D‐GalN acute liver failure

Endotoxin tolerance ameliorates lipopolysaccharide/D-galactosamine-induced acute liver failure by negative regulation of the NF-κB/NLRP3 and activation of Nrf2/HO-1 via Sitr1

Blood Coral Polysaccharide Helps Prevent D-Gal/LPS-Induced Acute Liver Failure in Mice

Assessment Of Free Radical Scavenging Activity Of Dimethylglycine Sodium Salt And Its Role In Providing Protection Against Lipopolysaccharide-Induced Oxidative Stress In Mice

Chrysophanol-8-O-glucoside protects mice against acute liver injury by inhibiting autophagy in hepatic stellate cells and inflammatory response in liver-resident macrophages

Chronic Systemic D‐galactose Exposure Induces Memory Loss, Neurodegeneration, and Oxidative Damage in Mice: Protective Effects of R‐α‐lipoic Acid

Early Use of Dexamethasone Increases Nr4a1 in Kupffer Cells Ameliorating Acute Liver Failure in Mice in a Glucocorticoid Receptor-Dependent Manner

Estrogen-Related Receptor γ Agonist DY131 Ameliorates Lipopolysaccharide-Induced Acute Liver Injury